Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

 v2.3.0.11
Condensed Consolidated Statements of Cash Flows (USD $)
In Thousands
6 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Cash Flows from operating activities:    
Net loss $ (1,987) $ (3,316)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 194 167
Share-based compensation expense 191 35
Gain on sale of asset (28) 0
Sales discounts and provision for bad debts (54) (105)
Inventory valuation provision (20) (823)
Changes in operating assets and liabilities:    
Accounts receivable 3,713 2,849
Inventory 108 1,075
Accounts payable (358) (476)
Accrued advertising and other allowances (1,722) (255)
Other operating assets and liabilities, net 512 194
Net cash provided by (used in) operating activities 549 (655)
Cash flows from investing activities:    
Capital expenditures (204) (116)
Proceeds from the sale of fixed assets 166 0
Acquisition of product license 0 (1,000)
Net cash flows used in investing activities (38) (1,116)
Cash flows from financing activities:    
Proceeds from exercise of stock options 0 133
Net cash provided by financing activities 0 133
Net increase (decrease) in cash and cash equivalents 511 (1,638)
Cash and cash equivalents at beginning of period 8,232 12,801
Cash and cash equivalents at end of period 8,743 11,163
Supplemental disclosures of cash flow information:    
Income taxes paid 0 0
Common stock issued to Phosphagenics Limited pursuant to a product license agreement $ 0 $ 2,577